Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Windtree Therapeutics, Inc.    WINT

WINDTREE THERAPEUTICS, INC.

(WINT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/25/2020 11/27/2020 11/30/2020 12/01/2020 12/02/2020 Date
6.34(c) 6.69(c) 6.55(c) 6.24(c) 6.47 Last
2 652 6 548 9 383 6 346 3 264 Volume
-3.21% +5.52% -2.09% -4.73% +3.69% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -31,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -3,04x
Yield 2020 -
Sales 2021 1,40 M - -
Net income 2021 -30,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,46x
Yield 2021 -
Capitalization 106 M 106 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 75,4x
Nbr of Employees 32
Free-Float 20,0%
More Financials
Company
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved... 
More about the company
All news about WINDTREE THERAPEUTICS, INC.
11/17WINDTREE THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Provide..
AQ
11/16WINDTREE THERAPEUTICS : November '20 Corporate Presentation
PU
11/16WINDTREE THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Provide..
PR
11/16WINDTREE THERAPEUTICS INC /DE/ : Results of Operations and Financial Condition, ..
AQ
11/16WINDTREE THERAPEUTICS : DE/ Management's Discussion and Analysis of Financial Co..
AQ
10/02WINDTREE THERAPEUTICS : Announces First Patient Dosed in Phase 2 Study of Istaro..
AQ
10/01WINDTREE THERAPEUTICS INC /DE/ : Other Events, Financial Statements and Exhibits..
AQ
10/01WINDTREE THERAPEUTICS : Announces First Patient Dosed in Phase 2 Study of Istaro..
PR
09/29WINDTREE THERAPEUTICS INC /DE/ : Other Events, Financial Statements and Exhibits..
AQ
09/29WINDTREE THERAPEUTICS : Announces FDA Acceptance of IND Application for a Phase ..
PR
09/17WINDTREE THERAPEUTICS INC /DE/ : Entry into a Material Definitive Agreement, Fin..
AQ
09/09WINDTREE THERAPEUTICS : to Present at H.C. Wainwright 22nd Annual Global Investm..
AQ
09/08WINDTREE THERAPEUTICS : to Present at H.C. Wainwright 22nd Annual Global Investm..
PR
08/20WINDTREE THERAPEUTICS INC /DE/ : Regulation FD Disclosure, Financial Statements ..
AQ
08/14WINDTREE THERAPEUTICS : DE/ Management's Discussion and Analysis of Financial Co..
AQ
More news
News in other languages on WINDTREE THERAPEUTICS, INC.

- No features available -

More news
Chart WINDTREE THERAPEUTICS, INC.
Duration : Period :
Windtree Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 12,25 $
Last Close Price 6,24 $
Spread / Highest target 96,3%
Spread / Average Target 96,3%
Spread / Lowest Target 96,3%
EPS Revisions
Managers
NameTitle
Craig E. Fraser President, Chief Executive Officer & Director
Zuie Chin Huang Chairman
Eric L. Curtis Chief Operating Officer & Senior Vice President
John P. Hamill Chief Financial Officer & Senior Vice President
Steven G. Simonson Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
WINDTREE THERAPEUTICS, INC.-51.06%106
MODERNA, INC.620.91%55 799
LONZA GROUP AG56.57%45 596
CELLTRION, INC.91.71%41 539
IQVIA HOLDINGS INC.10.82%32 829
SEAGEN INC.55.27%31 988